ACES Professor Gordon Wallace with the PICT 3D Printer.
Original Published Date: 
Wednesday, December 6, 2017

In an Australian first, researchers at the Australian Research Council (ARC) Centre of Excellence for Electromaterials Science (ACES), based at the University of Wollongong (UOW) have designed and built a customised 3D bioprinter that promises to revolutionise treatment for people with Type 1 Diabetes.

The printer will be capable of delivering insulin-producing islet cells from a protective bioink into a printed scaffold suitable for transplant.

The Pancreatic Islet Cell Transplantation (PICT) 3D Printer was officially handed over to South Australian Minister for Health Peter Malinauskas for use at the Royal Adelaide Hospital (RAH), by ACES Executive Director and Australian National Fabrication Facility (ANFF) Materials Director, Professor Gordon Wallace.

The RAH is the first hospital in Australia to receive this cutting edge biomedical printing device, developed by researchers from ACES and ANFF Materials, headquartered at UOW. The PICT Printer will be developed further with funding from an ARC Linkage, Infrastructure, Equipment and Facilities (LIEF) grant.

Professor Wallace said the development and hand over of the PICT Printer marked a new era in manufacturing as ACES researchers continue to expand their clinical connections and explore new opportunities for customised 3D bioprinters and bioink formulations.

Media issued by the University of Wollongong.

Photo credit: 

Image: ACES Professor Gordon Wallace with the PICT 3D Printer.
Credit: University of Wollongong Media